https://www.selleckchem.com/pr....oducts/Avasimibe(CI-
32%; PFS 2.00%). The absolute difference then became negative, indicating more censoring in the experimental arm as time progressed (end-of-study OS -7.54%; PFS -9.09%). Differences in censoring between control and experimental arms of cancer RCTs suggest that there could be systematic bias present at various study time points that may influence key results. Further investigation is needed, as possible reasons include study assignment disappointment, inappropriate follow-up length, lack of efficacy, or intolerable toxicity, e
Gefällt mir
Kommentar
Teilen
